Pathfinders in Biopharma

5.0 (12)
INVERSIONES
CADA DOS MESES

Perspectives from the cutting edge of biotech and pharma. The fast-changing world of biopharma places a premium on trusted market insights from industry experts who can turn change into a competitive advantage. Stay ahead of the curve with our latest podcast series. Lead today. Define tomorrow.

22 NOV

Unlocking Biotech’s Potential: Strategies for Navigating Public and Private Market Investments

Innovation is surging in the U.S biotechnology sector, so why are investors still fearful about committing? Noël Brown, Head of U.S. Biotechnology Investment Banking at RBC Capital Markets, is joined by fund founders Craig Gordon, MD, CEO and CIO at GordonMD® Global Investments LP and Srini Akkaraju, MD, PhD, Managing Partner at Samsara BioCapital, to analyze the prospects for a full return of capital to the sector.

23 min
30 SEPT

Former Investor Who Chose Broadcasting Over Biotech ETFs

Former biotech investor, Brad Loncar has pivoted his career from investing to reporting on the industry. Instead of serving the biotech bubble, he hopes to reach a wide audience with interest in science. Loncar explains why he switched careers and sets out his ambitions for his channel, Biotech TV.

12 min
29 AGO

Can AI Solve Molecule Mysteries that will Unlock Simpler Drug Discovery?

The hardest parts of drug discovery will be vastly simplified if the mysteries of molecules and proteins can be cracked. That may be beyond human capabilities – but AI is working hard on it. In this episode of RBC’s Pathfinders in Biopharma, Noël Brown is joined by Clarissa Desjardins, CEO of Congruence, and Laksh Aithani, CEO and Co-founder of Charm Therapeutics, to discuss how far the tech can take us.

34 min
19 JUL

Shots-on-Goal Licensing Company Aims for Breakthroughs

A very special breed of animals is helping biotech and pharma companies in the quest for new human therapeutics. CFO Kurt Gustafson joins Pathfinders in Biopharma to explain the technologies behind OmniAb’s business model.

14 min
11 JUL

Why Biopharma Needs to Tell Better Stories on Novel Drugs

Ronald Martell is a serial entrepreneur and biopharma veteran whose record includes the launch of Herceptin. He continues his mission to bring new drugs to patients with unmet medical needs. The CEO of Jasper Therapeutics explains his ambitions for his company’s new antibody therapy and for the future of the industry.

16 min
8 JUL

Venture capital velocity: What’s driving renewed momentum in biotech?

In biotech, a recovery is already well underway. Expected interest rate cuts and improving valuations across public and private markets are creating a compelling environment for deals, entrances, exits, and trades to take shape. In this episode, biotech venture capital experts assess the sector’s sharper focus on funding fundamental science, evolving deal structures, including the return of reverse mergers and dual-track processes, and the key therapeutic modalities that are driving momentum in the market. Hear from Andrew Aherrera, Partner at Panacea Venture; Jeni Lee, Partner at Pivotal Life Sciences; Regina Salvat, Principal at Sofinnova; and Noël Brown, Head of US Biotechnology Investment Banking at RBC Capital Markets, as they share their fresh perspectives on the dynamic forces propelling the biotech industry forward.

35 min
21 JUN

Pharma Understands Phase One Data – But Does the Market?

Public biotech Pyxis Oncology is taking forward its innovative work on ADCs. President and CEO, Lara Sullivan, explains the company’s journey to find the right investors, and why she believes the markets still have some learning to do when analyzing data from early-stage studies.

26 min
14 JUN

Davern Capital sees GLP-1 Opportunities Beyond Obesity

Davern Capital’s founder, Elie Kobrin, approaches the biopharma market from a long/short perspective – but as a former doctor, he also speaks the language of medicine. He explains the fund’s approach and offers insights on hot topics in the current market.

10 min

Ver todo (45)

5

de 5

12 calificaciones

JMC

06/07/2021

JCChat109

Rare to find a podcast focused on the capital markets side of biotech. Very substantive and knowledgeable conversations. Great episode with Omega and Nuvation, keep those coming!
Learned Tons!

26/01/2021

Sal from Cambridge

I’m a seasoned angel investor in biotech and I find this podcast really valuable. Every episode has added to my knowledge of both the science and the finance. It fills an important void in the podcast space. Well done team RBC Capital Markets.
Great podcast!

05/01/2021

GloriaM21

Very informative!
Great Insights

30/12/2020

Mzushi

I enjoyed every episode, looking forward to more insight.

Perspectives from the cutting edge of biotech and pharma. The fast-changing world of biopharma places a premium on trusted market insights from industry experts who can turn change into a competitive advantage. Stay ahead of the curve with our latest podcast series. Lead today. Define tomorrow.